Cargando…

The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease

Huntington’s disease (HD) is caused by an expansion mutation of a CAG repeat in exon 1 of the huntingtin (HTT) gene, that encodes an expanded polyglutamine tract in the HTT protein. HD is characterized by progressive psychiatric and cognitive symptoms associated with a progressive movement disorder....

Descripción completa

Detalles Bibliográficos
Autores principales:	Heinz, Annika, Schilling, Judith, van Roon-Mom, Willeke, Krauß, Sybille
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517220/ https://www.ncbi.nlm.nih.gov/pubmed/34659371 http://dx.doi.org/10.3389/fgene.2021.761714

Ejemplares similares

Juvenile‐Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review
por: Bakels, Hannah S., et al.
Publicado: (2021)

Statistical method for modeling sequencing data from different technologies in longitudinal studies with application to Huntington disease
por: Fuady, Angga M., et al.
Publicado: (2020)

Making (anti-) sense out of huntingtin levels in Huntington disease
por: Evers, Melvin M, et al.
Publicado: (2015)

Pathological characterization of T2*-weighted MRI contrast in the striatum of Huntington’s disease patients
por: Bulk, Marjolein, et al.
Publicado: (2020)

Common disease signatures from gene expression analysis in Huntington’s disease human blood and brain
por: Mina, Eleni, et al.
Publicado: (2016)

Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington’s disease peripheral blood samples
por: Mastrokolias, Anastasios, et al.
Publicado: (2016)

Post‐mortem 7T MR imaging and neuropathology in middle stage juvenile‐onset Huntington disease: A case report
por: Bakels, Hannah S., et al.
Publicado: (2022)

Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies
por: Evers, Melvin M., et al.
Publicado: (2013)

Bioenergetics in fibroblasts of patients with Huntington disease are associated with age at onset
por: Gardiner, Sarah L., et al.
Publicado: (2018)

The dynamics of early-state transcriptional changes and aggregate formation in a Huntington’s disease cell model
por: van Hagen, Martijn, et al.
Publicado: (2017)

Machine learning in Huntington’s disease: exploring the Enroll-HD dataset for prognosis and driving capability prediction
por: Ouwerkerk, Jasper, et al.
Publicado: (2023)

Co-expression Patterns between ATN1 and ATXN2 Coincide with Brain Regions Affected in Huntington’s Disease
por: Keo, Arlin, et al.
Publicado: (2017)

Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease
por: van Roon-Mom, Willeke MC, et al.
Publicado: (2008)

Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood
por: Mastrokolias, Anastasios, et al.
Publicado: (2015)

Effect of post-mortem delay on N-terminal huntingtin protein fragments in human control and Huntington disease brain lysates
por: Schut, Menno H., et al.
Publicado: (2017)

Inhibition of the MID1 protein complex: a novel approach targeting APP protein synthesis
por: Matthes, Frank, et al.
Publicado: (2018)

MicroRNAs miR-19, miR-340, miR-374 and miR-542 regulate MID1 protein expression
por: Unterbruner, Kristoffer, et al.
Publicado: (2018)

GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study
por: Tramutola, Antonella, et al.
Publicado: (2023)

Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias
por: Buijsen, Ronald A.M., et al.
Publicado: (2019)

Huntington's Disease: A Clinical Review
por: Andhale, Rajeshwar, et al.
Publicado: (2022)

miRNA therapeutics in cardiovascular diseases: promises and problems
por: Nouraee, Nazila, et al.
Publicado: (2015)

Therapeutic Strategies for Spinocerebellar Ataxia Type 1
por: Kerkhof, Laurie M. C., et al.
Publicado: (2023)

Regulation of mRNA Translation by MID1: A Common Mechanism of Expanded CAG Repeat RNAs
por: Griesche, Nadine, et al.
Publicado: (2016)

Management of Agitation in Huntington’s Disease: A Review of the Literature
por: Rossi, Garrett, et al.
Publicado: (2020)

The Effect of Huntington’s Disease on the Basal Nuclei: A Review
por: Matz, Olivia C, et al.
Publicado: (2022)

Antisense-Mediated RNA Targeting: Versatile and Expedient Genetic Manipulation in the Brain
por: Zalachoras, Ioannis, et al.
Publicado: (2011)

Suppression of trinucleotide repeat expansion in spermatogenic cells in Huntington’s disease
por: Cho, In K., et al.
Publicado: (2022)

Huntington’s disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer’s disease
por: Hensman Moss, Davina J., et al.
Publicado: (2017)

Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide
por: Evers, Melvin M., et al.
Publicado: (2011)

Unraveling Huntington’s Disease: A Report on Genetic Testing, Clinical Presentation, and Disease Progression
por: Ahmed, Moutushi, et al.
Publicado: (2023)

A Systematic Review of Transcriptional Dysregulation in Huntington’s Disease Studied by RNA Sequencing
por: Malla, Bimala, et al.
Publicado: (2021)

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice
por: Toonen, Lodewijk J.A., et al.
Publicado: (2017)

On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson’s and Huntington’s Disease
por: Troncoso-Escudero, Paulina, et al.
Publicado: (2020)

Antisense Oligonucleotide-Induced Amyloid Precursor Protein Splicing Modulation as a Therapeutic Approach for Dutch-Type Cerebral Amyloid Angiopathy
por: Daoutsali, Elena, et al.
Publicado: (2021)

Huntington's Disease as Neurodevelopmental Disorder: Altered Chromatin Regulation, Coding, and Non-Coding RNA Transcription
por: Kerschbamer, Emanuela, et al.
Publicado: (2016)

Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers
por: Punnia-Moorthy, Gaya, et al.
Publicado: (2021)

Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3
por: Toonen, Lodewijk J. A., et al.
Publicado: (2016)

Huntingtin and Its Role in Mechanisms of RNA-Mediated Toxicity
por: Heinz, Annika, et al.
Publicado: (2021)

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives
por: Synofzik, Matthis, et al.
Publicado: (2022)

Promises and pitfalls of immune-based strategies for Huntington's disease
por: Colpo, Gabriela Delevati, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g82c8daajh5bhki12d5c2cnnov